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ABSTRACT 
BACKGROUND:  In the general population, selective cyclooxygenase (COX)-2 
inhibitors have been associated with fewer gastrointestinal dverse ffects (AEs) than 
NSAIDs, but whether they are associated with exacerbations in patients with inflam- 
matory bowel disease (IBD) remains controversial. 
OBJECT IVE:  The aim of this study was to review published and unpublished 
findings to determine whether the use of COX-2 inhibitors increased the risk for IBD 
exacerbations relative to placebo in the treatment of IBD. 
METHODS:  A systematic search of MEDLINE (1966-July 2007), EMBASE (1980- 
July 2007), the Cochrane Library (2007 Issue 4), US Food and Drug Administration 
records, and data on file at Novartis Pharmaceuticals Corporation, Pfizer US Pharma- 
ceutical Group, and Merck & Co., Inc., using the search terms celecoxib, rofecoxib, valdecoxib, 
etoricoxib, lumiracoxib, cyclooxygenase 2 inhibitor, Crohn's disease, ulcerative colitis, and inflam- 
matory bowel disease, was performed to identify randomized, placebo-controlled clinical 
trials of 5 COX-2 inhibitors in patients with IBD. The publications were fully reviewed 
for quality. Data on trial design, patient characteristics, intervention drugs, dosages, and 
outcomes were collected using a predetermined data-extraction form. A meta-analysis 
was performed based on the publications that met the inclusion/exclusion criteria. 
RESULTS"  Of 588 studies identified in the electronic search, 574 were excluded 
after screening the titles and abstracts. Fourteen related to the use of COX-2 inhibitors in 
patients with IBD were reviewed. Two randomized, controlled trials comparing COX-2 
inhibitors with placebo were identified. In the first trial, 82 patients were randomized 
to receive etoricoxib (60-120 mg/d) and 77 to receive placebo. The exacerbation rates 
were 10.5% (8/76) in the active-treatment group and 11.4% (8/70) in the placebo group 
(relative risk [RR], 0.92; 95% CI, 0.37-2.32). In the second trial, 112 patients were 
treated with celecoxib (200 mg BID) and 110 received placebo. The exacerbation rates 
were 3.7% (4/107) in the celecoxib group and 2.7% (3/110) in the placebo group (RR, 
0.73; 95% CI, 0.17-3.18). Of these patients, 5 were lost to follow-up because of AEs. 
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In the meta-analysis comparing COX-2 inhibitors and placebo, the RR was 0.86 (95% 
CI, 0.39-1.88). No statistically significant differences in IBD relapse rates were found 
between COX-2 inhibitors and placebo. 
CONCLUSIONS:  The results from this meta-analysis suggest hat insufficient 
data were available to determine the'impact of COX-2 inhibitors on IBD exacerbations. 
The relatively smaller isk for AEs makes the short-term use of COX-2 inhibitors poten- 
tially attractive, but the long-term benefits remain unclear. Further studies with sound 
methodology and large sample sizes are needed to evaluate the tolerability of COX-2 
inhibitors in the treatment of IBD. (Curr Ther Res Clin Exp. 2008;69:181-191) © 2008 
Excerpta Medica Inc. 
KEY WORDS:  meta-analysis, cyclooxygenase-2 inhibitor, Crohn's disease, ulcera- 
tive colitis, inflammatory bowel disease. 
INTRODUCTION 
Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease 
(CD), is a group of chronic, relapsing inflammatory diseases of the intestinal tract that 
are characterized by a lifelong course with remissions and exacerbations. The disease 
affects >3.5 million people in the United States and Europe) ,2 Despite intensive inves- 
tigation into the cause and pathogenesis of IBD, its pathogenic mechanism has not been 
elucidated) The response of the individual patient with IBD to treatment is variable. 
Therefore, the goals for IBD therapy should be to decrease the number of relapses, 
prolong remission, and improve quality of life. 4 
Conventional NSAIDs are used to reduce inflammatory pain and swelling. These 
drugs might be used in the treatment of musculoskeletal pain and stiffness. IBD may 
be complicated by arthropathies, for which NSAIDs would be appropriate treatment. 
However, their long-term use is limited by gastrointestinal (GI) adverse ffects (AEs)) ,6 
Serious NSAID-induced GI AEs (eg, hemorrhage, perforation, death) occur in 1% to 2% 
of patients who use NSAIDs daily for a year? Several studies have found that the use 
of NSAIDs was associated with the onset of IBD or a clinical exacerbation of IBD. 8-1° 
Therefore, it is widely believed that these drugs should not be used by patients with a 
history of IBD. 
IBD has been associated with a variety of extraintestinal manifestations, including 
4 categories of rheumatologic disease: peripheral arthritis, spondylitis, sacroiliitis, and 
a broad group of less common rheumatologic disorders) 1,12 Despite the GI AEs associ- 
ated with NSAIDs, these drugs are also widely prescribed for the treatment of pain 
and stiffness in these rheumatologic conditions. As an alternative to NSAIDs, selective 
cyclooxygenase (COX)-2 inhibitors were developed to provide better GI tolerability. 
COX is a rate-limiting enzyme that catalyzes the formation of prostanoids from 
arachidonic acid. There are 2 isoforms of COX: COX-1 and COX-2. COX-1 is involved 
in the production of prostaglandins that are essential for the maintenance of normal 
endocrine and kidney function, gastric mucosal integrity, and coagulation. In contrast, 
COX-2 is normally undetectable in most tissues but is produced in response to inflam- 
matory and mitogenic stimuli, suggesting that it has an important role in mediating 
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inflammation33 Whereas NSAIDs inhibit the activity of the 2 forms of COX, COX-2 
inhibitors are more selective 14 and in the general population are associated with fewer 
GI AEs than NSAIDs. 15,16 However, whether COX-2 inhibitors can be used safely in 
patients with IBD remains controversial. Several studies 17-21 have examined the clinical 
outcomes of COX-2 inhibitors in IBD, but the results were not consistent. Some inves- 
tigators reported acceptable toxicity profiles with these drugs, 17,1s but others reported 
high frequencies of disease xacerbation. 19-2t 
The objective of this study was to evaluate the association of 5 COX-2 inhibitors 
(celecoxib, rofecoxib, valdecoxib, etoricoxib, and lumiracoxib) with IBD exacerbations 
and to identify gaps in knowledge that will suggest he most fruitful direction for 
future research. 
MATERIALS  AND METHODS 
The primary end point of this review was patient outcome, as measured using the IBD 
exacerbation rate. 
SEARCH STRATEGY 
We took 3 steps to identify prospective, randomized, controlled clinical trials of 
selective COX-2 inhibitors versus placebo. First, we approached the manufacturers of
each of the 5 selective COX-2 inhibitors--Merck & Co., Inc. (rofecoxib and etoricoxib), 
Novartis Pharmaceuticals Corporation (lumiracoxib), and Pfizer US Pharmaceutical 
Group (celecoxib and valdecoxib). Second, MEDLINE (1966-July 2007), EMBASE 
(1980-July 2007), and the Cochrane Library (2007 Issue 4) were searched for published 
studies. The search was restricted to studies in adults, and no language restrictions were 
used. The initial search used the key words cdecoxib, rofecoxib, valdecoxib, etoricoxib, lumira- 
coxib, cydooxygenase 2 inhibitor, Crohn's disease, ulcerative colitis, and inflammatory bowel dis- 
ease. Abstracts of the trials identified by the electronic searches were reviewed, and trials 
of any of the 5 COX-2 inhibitors in the treatment of IBD were retrieved for detailed 
evaluation. Review articles were examined to identify additional articles. Personal cor- 
respondence with authors was sought o clarify details of trials, when necessary. Third, 
the US Food and Drug Administration electronic database 22was searched for clinical 
trial data that were unavailable in publications identified through MEDLINE. 
INCLUSION CRITERIA 
Randomized clinical trials in patients with IBD that compared therapy with COX-2 
inhibitors and placebo were considered for inclusion. Data were obtained on adult 
patients (aged _>18 years) with a diagnosis of IBD (either UC or CD defined by a combi- 
nation of clinical, radiographic, endoscopic, and histologic riteria) of_>4-week duration. 
Electrophysiologic and animal studies were excluded from the search. 
DATA EXTRACTION 
For each included trial, data on trial design, patient characteristics, intervention 
drugs, dosages, and outcomes were collected using a predetermined data-extraction 
form. Discrepancies between the authors' assessments of the articles were resolved by 
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referring to the original papers and discussion. Any remaining differences were resolved 
with the help of an independent expert gastroenterologist or statistician. 
QUALITY ASSESSMENT 
All studies were scored for quality by 2 reviewers working independently (X.-P.M., 
H.-Y.L.) using a modification of the scale developed by Jadad et al. 23 
STAT IST ICAL  ANALYS IS  
ReviewManager 4.2.9 (San Francisco, California) was used to analyze the dichotomous 
data obtained from this review. Relative risk (RR) was used to assess all dichotomous out- 
come measures. We used the fixed-effects model and presented the data with 95% CIs. 
RESULTS 
This search yielded a total of 588 articles from the electronic databases. Of these, 
574 articles were excluded after screening of titles and abstracts. We analyzed the full 
text of 14 papers about the use of COX-2 inhibitors in patients with IBD (Figure 1). 
In the meta-analysis, we included 2 randomized controlled trials involving 381 par- 
ticipants. The adequacy of randomization, blinding, and completeness of follow-up were 
determined for each study (Table I24,25). Scores ranged from 0 to 5, with a score <3 
indicating poor quality. 
The quality of 2 randomized, ouble-blind, placebo-controlled trials was found to 
be satisfactory for inclusion in the meta-analysis. The characteristics of these 2 studies 
are summarized in Table II. 24,25 The intervention and control groups were similar in 
the 2 studies. Data collection was identical before and after the intervention, and losses 
to follow-up were minimal in both studies. 
Both studies provided sufficient information for analysis (Table I). The study by 
Sandborn et a125 was classified as clear allocation concealment, while the study by E1 
Miedany et a124 was initially classified as unclear allocation concealment. The study authors 
were contacted for further information. Based on the authors' responses, the study clas- 
sification was changed to adequate allocation concealment. Study duration ranged from 
2 to 12 weeks, age and sex distributions were generally comparable across trials, and all 
study participants had IBD-complicated arthropathies. 
We excluded 12 studies lv-21'26-32 after a detailed review of the full text. Of these, 
8 studies were excluded because they were case reports and 4 were excluded because 
they were open-label studies. 
The study by El Miedany et a124 was conducted at 3 rheumatology centers in 
Egypt and Saudi Arabia (Table II). It enrolled 159 patients with UC or CD in remis- 
sion who had rheumatic symptoms. Of these, 82 patients were randomized to receive 
etoricoxib and 77 to receive placebo for 12 weeks; 13 patients were lost to follow- 
up. The index attributed points to clinical parameters, including disease activity 
score. The exacerbation rates were 10.5% (8/76) in the active-treatment group and 
11.4% (8/70) in the placebo group, with an RR of 0.92 (95% CI, 0.37-2.32). GI AEs 
were reported in 11% of the patients in the treatment group and led to premature 
withdrawal in 3%. 
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588 Potentially relevant 
articles identified 
i 
14 Articles selected for 
review of full text 
2 Articles included in the 
analysis 
574 Articles excluded 
after screening of titles 
and abstracts 
12 Articles excluded 
Figure 1. Literature search of MEDLINE, EMBASE, Cochrane Library, and US Food and 
Orug Administration electronic database. 
The study by Sandborn et a125 was conducted at 34 medical centers in 8 countries 
and enrolled 222 patients with UC and joint pain that was in clinical remission (Table 
II). One hundred twelve patients were randomized to receive celecoxib 200 mg BID 
and 110 patients received placebo for 14 days. Five patients were withdrawn due to 
AEs. The index attributed points to clinical parameters, including evidence of disease 
exacerbation. The exacerbation rate was 3.7% (4/107) in the celecoxib group compared 
with 2.7% (3/110) in the placebo group (RR, 0.73; 95% CI, 0.17-3.18). 
Heterogeneity was not observed uring the 2 clinical trials. The results of the meta- 
analysis comparing the COX-2 inhibitors with placebo found an RR of 0.86 (95% CI, 
0.39-1.88) (Figure 224,25). The differences in the descriptions of the AEs made them 
incomparable between the 2 studies. The proportions of patients reporting any AE were 
not significantly different between the celecoxib and placebo groups (21% and 17%, 
respectively). No serious AEs were reported. 
Table I. Quality assessment of the 2 studies included in the meta-analysis using a modi- 
fication of the scale developed by Jadad et al. 23 
Study Design 
Allocation Withdrawal/Loss Baseline Scale 
Concealment to Follow-Up Comparability Scores 
El Miedany et a124 Randomized, Adequate Mentioned Yes 5 
double-blind 
Sandborn et a125 Randomized, Adequate Mentioned Yes 5 
double-blind 
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Table II. Characteristics of the 2 Identified trials of cyclooxygenase (COX)-2 inhibitors 
for the treatment of Inflammatory bowel disease (IBD). 
Study El Miedany et a124 Sandborn et a125 
Location 3 Rheumatology centers in 34 Medical centers in Argentina, Canada, 
Egypt and Saudi Arabia Croatia, Denmark, Russia, Sweden, 
Turkey, and the United States 
Multicenter, randomized, double-blind, 
placebo-controlled 
Design 
Duration 
Participants 
Multicenter, randomized, 
double-blind, placebo- 
controlled 
12 Weeks 
CD (n = 76) or UC (n = 70) 
Age range: 18-65 y 
Inclusion criteria: patients 
with IBD attending the 
rheumatology clinics 
because of rheumatologic 
manifestations 
Exclusion criteria: preg- 
nancy, current smoker or 
former smoker for <1 y, or 
receiving antibiotic therapy 
Intervention Etoricoxib 60-120 mg/d, 
according to the rheumatic 
condition, for 3 months 
Outcome Exacerbation of IBD Exacerbation of IBD 
Relative risk 0.92 (0.37-2.32) 0.73 (0.17-3.18) 
(95% Cl) 
14 Days 
UC (n = 222) 
Age range: 18-75 y 
Inclusion criteria: patients who were 
defined as being in clinical remission of 
UC and joint pain, with a present or his- 
tory of nonspecific arthritis, arthralgia, 
or another condition amenable to NSAID 
therapy 
Exclusion criteria: active UC; a history 
of gastroduodenal ulcer within 1 month; 
received any NSAID, antiulcer drug, or 
antacid within 2 weeks; received cor- 
ticosteroids within 1 month; needed 
treatment with antibiotics, analgesics, or 
corticosteroids during the study; or had a 
known sulfa allergy and/or hypersensitiv- 
ity to COX-2 inhibitors 
Oral celecoxib 200 mg or placebo BID for 
14 days 
CD = Crohn's d isease;  UC = ulcerative colit is.  
DISCUSSION 
When comparing the clinical efficacy and tolerability of therapeutic agents within the 
same class, head-to-head, randomized, ouble-blind, controlled clinical trials are recog- 
nized as the "gold standard." In the absence of such rigorously designed, directly com- 
parable trials, indirect comparisons of different pharmacologic agents have been per- 
formed in meta-analyses. Meta-analytic approaches have been found to be feasible for 
systematic review of clinical studies. 33,34 In a meta-analysis, the criteria for inclusion of 
trials include similar mechanisms of action of the agents, the use of standardized pro- 
tocols in clinical trials, common demographic characteristics of the study participants, 
and comparison with a similar control, such as placebo. 35 
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Since the introduction of COX-2 inhibitors, some trials have directly compared indi- 
vidual COX-2 inhibitors with either placebo r NSAIDs in patients with IBD. 36'37 
However, a limited number of published trials 38,39 have directly compared _>2 dif- 
ferent COX-2 inhibitors. No published meta-analyses have examined the tolerability of 
different COX-2 inhibitors for the treatment of IBD. 
Sandborn et a125 found evidence that the COX-2 inhibitor celecoxib, currently the 
only COX-2 inhibitor available in the United States, was not associated with an in- 
creased relapse rate over 14 days in patients with UC in remission. E1 Miedany et a124 
assessed the tolerability of a different COX-2 inhibitor, etoricoxib, in a much broader 
group of patients with IBD. In that study, patients with CD or UC who had rheumatic 
symptoms were randomized to receive etoricoxib or placebo for 12 weeks. That study 
found that COX-2 inhibitors may be well tolerated in a broader group of patients with 
IBD and for a longer time. In general, the heterogeneity may be attributable to dif- 
ferences in study design, study populations, and drug mechanisms of action. In these 
clinical trials of COX-2 inhibitors, the differences in findings may have been due to 
several causes, such as the definition of a symptomatic exacerbation and the timing of 
drug administration. 
Similarly, Reinisch et a117 administered rofecoxib at a dosage of<25 mg/d for 20 days in 
32 patients with IBD and arthropathy. At day 20, the patients were assessed for dis- 
ease activity and response to treatment. Two patients with CD discontinued treatment 
because of diarrhea nd bleeding from a perianal fistula. One patient with indeterminate 
colitis discontinued treatment because of nausea. That perspective, open-label study did 
not find any exacerbation of the intestinal disease. Results from another etrospective 
analysis of celecoxib or rofecoxib in patients with IBD (treatment duration, 1 week- 
22 months) supported the tolerability of the COX-2 inhibitors. 2v 
In contrast to the generally positive assessment of the tolerability of COX-2 inhibi- 
tors in patients with IBD, Biancone t al 2° and Matuk et a121 found that COX-2 inhibi- 
tors may increase the relapse rate in patients with IBD. Biancone t al 2° treated patients 
with IBD and arthralgia with 12.5 mg/d rofecoxib for 12 weeks. Controls were patients 
with dyspepsia nd arthralgia. Two of 18 patients with CD developed iarrhea or 
abdominal pain, and 2 of 3 patients with UC developed heartburn or bloody diarrhea. 
No controls experienced AEs. The authors concluded that 19% of patients who received 
rofecoxib may have had clinical IBD exacerbation. Similarly, Matuk et a121 reported clini- 
cal relapse of the intestinal disease in 39% of 33 IBD patients who received celecoxib or 
rofecoxib. Because those studies lacked control arms, the results are difficult to inter- 
pret; however, the IBD exacerbation rates were generally higher in those studies than 
that in the control arm in the present analysis. 
In assessing the effects of COX-2 inhibitors in patients with IBD, it is important to sys- 
tematically analyze the studies of these drugs. The results from the present meta-analysis 
suggest that COX-2 inhibitors did not increase the relapse rate of patients with IBD in 
remission, indicating that COX-2 inhibitors may be generally well tolerated in patients 
with IBD. In addition to fewer GI AEs, this may be an advantage of COX-2 inhibitors 
over traditional nonselective NSAIDs. 15 Patients with IBD might have joint pain of longer 
duration and more inconvenient timing in terms of disease activity than remissions. 
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However, caution must be exercised by the physician in determining the use of 
COX-2 inhibitors in patients with IBD. The likely benefits and the possible AEs and 
toxicities of COX-2 inhibitors are largely based on animal data and case reports. The 
results from the present meta-analysis suggest that there were insufficient data, due to 
the short duration of follow-up and small sample sizes of the studies, to determine the 
role of COX-2 inhibitors in IBD exacerbations. 
CONCLUSIONS 
This meta-analysis found that insufficient data were available to determine the impact 
of COX-2 inhibitors on IBD exacerbations. The relatively smaller isk for AEs makes 
the short-term use of COX-2 inhibitors potentially attractive, but the long-term bene- 
fits remain unclear. Considering the short duration of follow-up and the small sample 
sizes of the studies we analyzed, we suggest hat further well-designed research with 
sound methodology and large sample sizes are needed to validate these observations in
the treatment of IBD. 
ACKNOWLEDGMENT 
The authors thank professor Tai-Xiang Wu, Clinical Epidemiology of West China 
Hospital of Sichuan University, Chengdu, China, for revising the manuscript. 
REFERENCES 
1. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and 
environmental influences. Gastroenterology. 2004;126:1504-1517. 
2. Andres PG, Friedman LS. Epidemiology and the natural course of inflammatory bowel disease. 
Gastroenterol Clin North Am. 1999;28:255-281. 
3. Fiocchi C. Inflammatory bowel disease: Etiology and pathogenesis. Gastroenterology. 1998;115:182- 
205. 
4. Isaacs KL, Lewis JD, Sandborn WJ, et al. State of the art: IBD therapy and clinical trials in IBD. 
lnflamm Bowel Dis. 2005;ll(Suppl 1):$3-S12. 
5. MacDonald TM, Morant SV, Robinson GC. Association of upper gastrointestinal toxicity of 
non-steroidal anti-inflammatory drugs with continued exposure: Cohort study. BMJ. 1997;315: 
1333-1337. 
6. Griffin MR, Scheiman JM. Prospects for changing the burden of nonsteroidal anti-inflammatory 
drug toxicity. AmJ Med. 2001;110(Suppl):33S-37S. 
7. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal com- 
plications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory d ugs. 
A randomized, ouble-blind, placebo-controlled trial. Ann Intern Med. 1995;123:241-249. 
8. Bjarnason I, Hayllar J, MacPherson AJ, Russell AS. Side effects of nonsteroidal anti-inflammatory 
drugs on the small and large intestine in humans. Gastroenterology. 1993;104:1832-1847. 
9. Felder JB, Korelitz BI, Rajapakse R, et al. Effects of nonsteroidal antiinflammatory drugs on 
inflammatory bowel disease: A case-control study. AmJ GastroenteroL 2000;95:1949-1954. 
10. Forrest K, Symmons D, Foster P. Systematic review: Is ingestion ofparacetamol or non-steroidal 
anti-inflammatory d ugs associated with exacerbations of inflammatory bowel disease? Aliment 
Pharmacol Ther. 2004;20:1035-1043. 
11. Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn's disease 
and ulcerative colitis: A study of 700 patients. Medicine (Baltimore). 1976;55:401-412. 
189 
CURRENT THERAPEUTIC  RESEARCH 
12. Rankin GB. Extraintestinal nd systemic manifestations of inflammatory bowel disease. Med 
Clin North Am. 1990;74:39-50. 
13. Crofford LJ, Lipsky PE, Brooks P, et al. Basic biology and clinical application of specific cyclo- 
oxygenase-2 inhibitors. Arthritis Rheum. 2000;43:4-13. 
i4. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. 
Nat New Biol. 1971;231:232-235. 
15. Bombardier C, Laine L, Reicin A, et al, for the VIGOR Study Group. Comparison of upper 
gastrointestinal toxicity of rofecoxib and naproxen i  patients with rheumatoid arthritis. N Engl 
J Med. 2000;343:1520-1528. 
16. Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen 
and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial 
(TARGET), reduction i  ulcer complications: Randomized controlled trial. Lancet. 2004;364:665- 
674. 
17. Reinisch W, Miehsler W, Dejaco C, et al. An open-label trial of the selective cyclo-oxygenase-2 
inhibitor, rofecoxib, in inflammatory bowel disease-associated peripheral rthritis and arthral- 
gia. Aliment Pharmacol Ther. 2003;17:1371-1380. 
18. Bonnet GF. Exacerbation of inflammatory bowel disease associated with use of celecoxib. AmJ 
Gastroenterol. 2001;96:1306-1308. 
19. Gornet JM, Hassani Z, Modiglian R, L~mann M. Exacerbation of Crohn's colitis with severe 
colonic hemorrhage in a patient on rofecoxib. AmJ Gastroenterol. 2002;97:3209-3210. 
20. Biancone L, Tosti C, Geremia A, et al. Rofecoxib and early relapse of inflammatory bowel dis- 
ease: An open-label trial. Aliment Pharmacol Ther. 2004;19:755-764. 
21. Matuk R, Crawford J, Abreu MT, et al. The spectrum of gastrointestinal toxicity and effect on 
disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel 
disease. Inflamm Bowel Dis. 2004;10:352-356. 
22. Guidance, information sheets, and important notices on good clinical practice in FDA-regulated 
clinical trials [US Food and Drug Administration Web site], http://www.fda.gov/oc/gcp/ 
guidance.html. Accessed May 30, 2008. 
23. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical 
trials: Is blinding necessary? Control Clin Trials. 1996;17:1-12. 
24. El Miedany Y, Youssef S, Ahmed I, E1 Gaafary M. The gastrointestinal safety and effect on 
disease activity of etoricoxib, aselective COX-2 inhibitor in inflammatory bowel diseases. AmJ 
G astroenterol. 2006;101:311-317. 
25. Sandborn WJ, Stenson WF, Brynskov J, et al. Safety of celecoxib in patients with ulcerative 
colitis in remission: A randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol. 
2006;4:203 -211. 
26. Goh J, Wight D, Parkes M, et al. Rofecoxib and cytomegalovirus in acute flare-up of ulcerative 
colitis: Coprecipitants or coincidence? AmJ Gastroenterol. 2002;97:1061-1062. 
27. Freedman GM, Kreitzer JM, Badola R. Rofecoxib-associated upper gastrointestinal bleed: A 
case report. Mt Sinai J Med. 2002;69:105-106. 
28. Mahadevan U, Loftus EV Jr, Tremaine WJ, Sandborn WJ. Safety of selective cyclooxygenase-2 
inhibitors in inflammatory bowel disease. AmJ Gastroenterol. 2002;97:910-914. 
29. Charachon A, Petit T, Lamarque D, Soul~ JC. Acute ulcerative colitis in a patient reated with 
rofecoxib who took aspirin as self-medication. Gastroenterol Clin Biol. 2003;27:511-513. 
30. Wilcox GM, Mattia AR. Rofecoxib and inflammatory bowel disease: Clinical and pathologic 
observations. J Clin Gastroenterol. 2005;39:142-143. 
31. Rey P, Andriamanantena D, Carr~re C, et al. Ulcerating haemorrhagic colitis induced by cele- 
coxib [in French]. Presse Med. 2005;34:443-445. 
190 
X. -P .  M IAO ET  AL .  
32. Takeuchi K, Smale S, Premchand P, et al. Prevalence and mechanism of nonsteroidal nti- 
inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin 
Gastroenterol Hepatol. 2006;4:196-202. 
33. T•wheed TE. Published meta-analyses •f pharmac•l•gical therapies f•r •ste•arthritis. •ste•arthritis 
Cartilage. 2002;10:836-837. 
34. Eccles M, Freemantle N, Mason J, et al, for the North of England Non-Steroidal Anti- 
Inflammatory Drug Guideline Development Group. North of England evidence based guideline 
development project: Summary guideline for non-steroidal anti-inflammatory d ugs versus basic 
analgesia ntreating the pain of degenerative arthritis. BMJ. 1998;317:526-530. 
35. Lee C, Hunsche E, Balshaw R, et al. Need for common i ternal controls when assessing the 
relative fficacy of pharmacologic agents using a meta-analytic approach: Case study of cyclooxy- 
genase 2-selective inhibitors for the treatment ofosteoarthritis. Arthritis Rheum. 2005;53:510- 
518. 
36. Langman MJ, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of rofecoxib 
compared with NSAIDs.JAMA. 1999;282:1929-1933. 
37. Silverstein FE, Faich G, Goldstein JL, et al, for the Celecoxib Long-Term Arthritis Safety 
Study Group. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs 
for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. 
JAMA. 2000;284:1247-1255. 
38. McKenna F, Weaver A, Fiechmer JJ, et al. COX-2 specific inhibitors in the management 
of osteoarthritis of the knee: A placebo-controlled, randomized, ouble-blind study. J Clin 
Rheumatol. 2001;7:151-159. 
39. Gibofsky A, Williams GW, McKenna F, Fort JG. Comparing the efficacy of cyclooxygenase 
2-specific inhibitors in treating osteoarthritis: Appropriate trial design considerations and 
results of a randomized, placebo-controlled trial. Arthritis Rheum. 2003;48:3102-3111. 
ADDRESS CORRESPONDENCE TO:  Qin Ouyang, MD, Department of 
Gastroenterology, West China Hospital of Sichuan University, 17 Renmin Avenue, 
Chengdu 610041, Sichuan Province, China. E-mail: ouyangqinl@sina.com 
191 
